Astec Lifesciences (NSE:ASTEC) Accounts Receivable: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTEC Astec Lifesciences Ltd NSE:ASTEC
72 GF Score
Price ₹562.40
GF Value ₹914.20
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Astec Lifesciences Accounts Receivable?

Astec Lifesciences NSE:ASTEC +0.30% 72 Accounts Receivable is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ASTEC with a GF Score™ of 72/100 and a GF Value™ of ₹914.20 (Possible Value Trap). The stock has 4 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Astec Lifesciences's accounts receivables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Astec Lifesciences's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Astec Lifesciences's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ₹N/A.

Astec Lifesciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Astec Lifesciences's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/835.643*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Astec Lifesciences's accounts receivable are only considered to be worth 75% of book value:

Astec Lifesciences's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0+0.75 * 0+0.5 * 0-N/A
-0-0)/22.282
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Astec Lifesciences Accounts Receivable Related Terms

Astec Lifesciences Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Astec Lifesciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astec Lifesciences Accounts Receivable Chart

Astec Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,736.28 1,549.00 1,690.04 1,474.43 2,477.17

Astec Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,365.53 0.00 2,477.17 0.00
NSE:ASTEC
72GF Score
Astec Lifesciences Ltd NSE:ASTEC
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astec Lifesciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of ₹0 Mil mean?
Astec Lifesciences (NSE:ASTEC) has a Accounts Receivable of ₹0 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Astec Lifesciences and its competitors.
Is Astec Lifesciences' Accounts Receivable too high?
Astec Lifesciences' current Accounts Receivable is ₹0 Mil. Overall, Astec Lifesciences has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Accounts Receivable compare to CTVA and CF?
Astec Lifesciences' Accounts Receivable of ₹0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for an Agriculture company?
A good Accounts Receivable depends on the Agriculture industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Astec Lifesciences and its competitors. Astec Lifesciences's current Accounts Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹914.20, compared to a current price of ₹562.40 — trading 38.5% below its estimated fair value. The current Accounts Receivable is ₹0 Mil. Astec Lifesciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current Accounts Receivable is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?

Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued. The current stock price of ₹562.40 is trading 38.5% below its estimated GF Value™ of ₹914.20. GuruFocus considers Astec Lifesciences to be Possible Value Trap.

Key valuation signals for NSE:ASTEC:

  • Accounts Receivable: ₹0 Mil
  • GF Value™: ₹914.20 vs. price of ₹562.40 (38.5% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astec Lifesciences Business Description

Other Exchanges 533138:India
Address Eastern Express Highway, Godrej One, 3rd Floor, Pirojshanagar, Vikhroli (East), Mumbai, MH, IND, 400 079
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
72GF Score

Get the complete analysis for NSE:ASTEC

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹562.40
Price
₹914.20
GF Value